Nextech Invest Ltd.
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed November 14, 2025), Nextech Invest Ltd. reported 15 stock positions worth $657.0 million. Its top holding was Revolution Medicines (RVMD) at 54.0% of the portfolio, followed by Oric Pharmaceuticals (ORIC, 13.1%) and Tyra Biosciences (TYRA, 8.6%). Compared with Q2 2025, it sold out of 1 and reduced 1. The biggest sale was an exit from Cargo Therapeutics (CRGX).
- Most Recent 13F
- Q2 2026
- Location
- Zurich, V8
- CIK
- 0001595430
- Portfolio Value
- $657.0M (Q3 2025)
- SEC Filing
- 0001595430-25-000007 ↗ filed Nov 14, 2025
Holdings Value
Holdings 15 stocks · $657.0M
| RVMD Revolution Medicines Inc. | 54.03% | 7,601,087 | $355.0M | No change |
| ORIC Oric Pharmaceuticals Inc. | 13.08% | 7,162,637 | $86.0M | No change |
| TYRA Tyra Biosciences Inc. | 8.64% | 4,055,861 | $56.7M | No change |
| TNGX Tango Therapeutics Inc. | 7.08% | 5,533,980 | $46.5M | No change |
| RLAY Relay Therapeutics Inc. | 3.06% | 3,846,409 | $20.1M | No change |
| KYMR Kymera Therapeutics Inc. | 2.94% | 340,909 | $19.3M | No change |
| ZYME Zymeworks Inc. | 2.90% | 1,113,946 | $19.0M | No change |
| ARVN Arvinas Inc. | 1.83% | 1,408,394 | $12.0M | No change |
| ALMS Alumis Inc. | 1.77% | 2,915,998 | $11.6M | No change |
| CNTX Context Therapeutics Inc. | 1.09% | 7,419,355 | $7.2M | No change |
| CGEM Cullinan Therapeutics Inc. | 1.03% | 1,141,145 | $6.8M | No change |
| SPRY Ars Pharmaceuticals Inc. | 1.01% | 660,703 | $6.6M | Reduce -10.9% |
| SLN Silence Therapeutics PLC-ADR | 0.75% | 952,400 | $4.9M | No change |
| MRSN Mersana Therapeutics Inc. | 0.57% | 482,689 | $3.7M | No change |
| BOLD Boundless Bio Inc. | 0.23% | 1,228,069 | $1.5M | No change |
Portfolio Sells Q2 2025 → Q3 2025
Portfolio Buys Q2 2025 → Q3 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 15 | $2.1B | RVMD, PBLS, RLAY, TYRA, ALMS |
| Q1 2026 | 17 | $1.4B | RVMD, TYRA, TNGX, ORIC, ALMS |
| Q4 2025 | 16 | $1.0B | RVMD, TYRA, TNGX, ORIC, RLAY |
| Q3 2025 | 15 | $657.0M | RVMD, ORIC, TYRA, TNGX, RLAY |
| Q2 2025 | 16 | $528.4M | RVMD, ORIC, TYRA, TNGX, KYMR |
| Q1 2025 | 15 | $430.3M | RVMD, TYRA, ORIC, ZYME, SPRY |